Simulect 20 mg/5mL
basiliximab · INJECTION, POWDER, FOR SOLUTION · Novartis Pharmaceuticals Corporation
Simulect is a injection, powder, for solution containing basiliximab at 20 mg/5mL, taken intravenous. Manufactured by Novartis Pharmaceuticals Corporation.
Key Facts
- Brand Name
- Simulect
- Generic Name
- basiliximab
- NDC Code (Product)
0078-0331- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 20 mg/5mL
- Dosage Form
- INJECTION, POWDER, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA103764
- Drug Class
- Interleukin-2 Receptor Blocking Antibody [EPC]
- Marketing Start
- 05/12/1998
Recall History
No Recall HistoryFrequently Asked Questions
What is Simulect used for?
Simulect contains basiliximab. It is a injection, powder, for solution taken intravenous. Consult your doctor for specific uses.
Is Simulect a controlled substance?
Simulect is not classified as a controlled substance by the DEA.
What is the generic name for Simulect?
The generic name for Simulect is basiliximab. There are no other listed brand versions of basiliximab.
What is the NDC code for Simulect 20 mg/5mL?
The NDC (National Drug Code) for Simulect 20 mg/5mL is 0078-0331, listed by Novartis Pharmaceuticals Corporation.
Other Simulect Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)